Erasca, Inc. Authorized Dilution
Share-issuance capacity and approved equity plans, with the disclosed share class, period, approval and expiry. Gross charter headroom is authorized minus issued shares, not a forecast. Equity plan reserves may use weighted counting rules, overlap charter capacity, and must not be added to it. Outstanding awards, future grants, and proposed approvals are distinct. * denotes calculated capacity.
| As of | Authorization / plan | Share class | Authorized / approved limit (shares) | Issued shares / outstanding awards (shares) | Remaining capacity (shares / reserve units) | Approval status | Approval date | Expiry / conditions | Basis / limitations | Source |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|